Clinical trial
Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed…
NCT00367497 · Keio University, Other · Terminated
Key facts
| NCT number | NCT00367497 |
|---|---|
| Title | Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma |
| Official title | Phase 2 Study of Rituximab and ESHAP (Etoposide, Methylprednisolone, Cytarabine, and Cisplatin) in Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma |
| Lead sponsor | Keio University, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin |
| Intervention type | Drug |
| Interventions | Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin |
| Enrollment | 5 |
| Start date | Aug 1, 2005 |
| Completion | Nov 1, 2007 |
| First posted | Aug 23, 2006 |
| Last update posted | Nov 20, 2007 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: